Traditional treatment methods of kidney cancer Most of kidney cancers have an insidious course of development and do not show symptoms until they develop to a more advanced stage, and about 25% of patients have metastasis by the time they are detected. The current treatment methods of kidney cancer include surgery, chemotherapy, hormone therapy and immunobiotherapy. 1. With the advancement and wide popularity of imaging technology, the proportion of early-stage kidney cancer detected clinically is gradually increasing, and early-stage patients have good surgical effect and high cure rate. Moreover, the progress of minimally invasive surgery technology makes patients suffer less pain, and most of the kidney cancer patients treated in our hospital currently adopt laparoscopic radical kidney cancer surgery, which is less traumatic and has fast recovery. Although surgery is the main method to treat early kidney cancer and focal kidney cancer, literature reports that metastasis occurs in 20%-40% of patients after nephrectomy. 2.Kidney cancer is highly tolerant to chemotherapeutic drugs and hormones, and its therapeutic effect is similar to placebo, which is rarely used clinically. The efficiency of cytokines such as interleukin-2 or alpha interferon is low, only about 15%, and the toxicity of long-term treatment is so high that patients can hardly tolerate them and cannot insist on long-term use. 4. Kidney cancer is also not sensitive to radiation therapy, which can be applied when bone pain is caused by kidney cancer metastasis. Overall, it seems that regular physical examination and early detection and early surgery are the best treatment for kidney cancer. However, nearly 1/4 of the patients have metastasis at the time of consultation, and some of them will have metastasis after surgery, and the above-mentioned chemotherapy drugs and cytokines are not developed for the pathogenesis of kidney cancer. Therefore, the US Food and Drug Administration has not approved any drugs for the treatment of advanced kidney cancer in the past 13 years. Therefore, new molecular targeted therapies, which target the pathogenesis of kidney cancer, can effectively control the tumor. New targeted therapies 1. The so-called “targeted therapy”, in layman’s terms, means targeting a targeted site, and in kidney cancer molecular therapy, it means targeting protein molecules in kidney cancer cells. 2. Molecular targeting is the highest level of specificity in targeted therapy, targeting the links that may lead to cellular carcinogenesis, reversing the malignant biological behavior at the molecular level, thus inhibiting the growth of tumor cells and even making them fade away completely, which is a new biological treatment mode. At the same time, targeted therapy targets the difference between tumor cells and normal cells, and only attacks tumor cells, with very little impact on normal cells, so it has the characteristics of “stable, accurate and hard”. 3.Molecular targeted therapy is a “flash point” of tumor treatment, with its specificity and effectiveness, it has achieved great success and is the “hot spot” of treatment at home and abroad. Targeted therapy represents a new direction of tumor treatment. Currently, the US FDA has approved four targeted drugs for kidney cancer: Doxorubicin (Sorafenib); Sotan (Sunitinib), CCI-779 and Bevacizumab, while Doxorubicin and Sotan have been approved in China.